Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Inclusion Criteria: * Male or female \>= 18 years of age * Is willing and able to provide written informed consent for the trial * Has histological confirmation of breast carcinoma with a clinical diagnosis of IBC based on the presence of inflammatory changes in the involved breast, including diffuse erythema and edema (peau d'orange), with or without an underlying palpable mass involving the majority of the skin of the breast. Or the diagnosis confirmed by the MD Anderson IBC specialists. Pathological evidence of dermal lymphatic invasion should be noted but is not required for the diagnosis of IBC * Any prior treatments will be allowed except eribulin and/or any EP2/4 inhibitor * Has at least 2 weeks of untreated period from the previous treatment * Any receptor status for ER/PR and HER2. But for HER2+ type, must has failed trastuzumab, pertuzumab, and T-DM1 treatment. * NOTE: HER2 positive status is defined as strongly positive (3+) staining score by immunohistochemistry (IHC), or gene amplification using fluorescence in situ hybridization (FISH), if performed. If IHC is equivocal (2+). HER2 negative status, which is determined by assays using IHC require negative (0 or 1+) staining score. If IHC is equivocal (2+) staining score * Has a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 (only applies to phase II part) * NOTE: Measurable disease: Measurable lesions are defined as those that can be accurately measured in at lea…